Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of

Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor
Transformation and Potential Marker and Target of Aggressive Cancers

BUFFALO, N.Y., July 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI), Incuron, LLC, a joint venture between CBLI and Bioprocess
Capital Ventures, and Roswell Park Cancer Institute (RPCI) today announced the
publication of studies describing the Facilitates Chromatin Transcription
(FACT) complex as an accelerator of tumor transformation and a potential
marker and target for aggressive cancers in Cell Reports, a peer-reviewed
journal. FACT is the molecular target for Curaxins, a new class of anti-cancer
compounds being developed by Incuron. The reported studies were led by
scientists at RPCI.

Roswell Park Cancer Institute Logo

The FACT complex is involved in chromatin remodeling during transcription,
replication, and DNA repair. These studies confirm an association between
FACT and cancer by showing that FACT is expressed at higher levels in tumor
cell lines than in normal cells in vitro and that elimination of FACT
expression leads to reduced growth and decreased survival of tumor cells. The
published work concludes that FACT's role in cancer likely involves selective
chromatin remodeling of genes that stimulate proliferation, inhibit cell death
and differentiation, and regulate cellular stress responses, making it an
enabler of oncogene-induced transformation.

In addition, the studies establish a statistically significant association
between the frequency and level of FACT expression and tumor
aggressiveness.The studies demonstrated that FACT is predominantly expressed
in aggressive undifferentiated cancers that result in poor overall patient
survival because of the development of metastatic disease, irrespective of
tumor size at the time of diagnosis. This increases the potential value of
FACT as a prognostic marker, as FACT positivity of a primary tumor could be
used at a very early stage to determine the risk of future metastatic disease.

"This recent publication builds upon our previous work showing that FACT is
the molecular target of Curaxins," noted Katerina Gurova, M.D., Ph.D., a
researcher in the Department of Cell Stress Biology at RPCI and lead author.
"The data presented in the Cell Reports publication indicate that FACT is a
promising marker and target for subtypes of cancer characterized by high grade
and aggressiveness, and poor prognosis.This, together with the absence of
FACT expression in most normal tissues, suggests that pharmacological
inhibition of FACT using Curaxins could be an effective strategy to treat
types of cancer for which there are currently few treatment options."

Jean Viallet, M.D., Chief Development Officer at Cleveland BioLabs, stated,
"We are evaluating the enormous body of data collected by our collaborators on
FACT expression and its role in cancer progression in an effort to focus our
next trials with our lead Curaxin drug candidate, CBL0137.Our plan is to
enrich the upcoming study of the intravenous administration of CBL0137 in
patients with metastatic or unresectable advanced solid tumors and lymphomas
by including patients whose tumor types are dependent on transcriptional
oncogenes."

In March 2013, a Notice of Allowance was received from the U.S. Food and Drug
Administration for an Investigational New Drug Application for intravenous
administration of CBL0137. A Phase 1 single-agent dose-escalation study of
oral administration of CBL0137 in patients with advanced solid tumors that are
resistant or refractory to standard-of-care treatment is ongoing in the
Russian Federation.

The Cell Reports publication may be found online at:
http://cellreports.cell.com/.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at http://www.cbiolabs.com.

About Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in 2010
between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and
Cleveland BioLabs.Incuron is developing CBL0102 and CBL0137 for oncology and
orphan indications.To learn more about Incuron, LLC, please visit the
company's website at http://www.incuron.com/.

About Roswell Park Cancer Institute:

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent
and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in
the country to be named a National Cancer Institute-designated comprehensive
cancer center and remains the only facility with this designation in Upstate
New York. The Institute is a member of the prestigious National Comprehensive
Cancer Network, an alliance of the nation's leading cancer centers; maintains
affiliate sites; and is a partner in national and international collaborative
programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI
(1-877-275-7724) or email askrpci@roswellpark.org. Follow Roswell Park on
Facebook and Twitter.

This press release contains certain forward-looking information about
Cleveland BioLabs that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully develop and
commercialize our therapeutic products; our ability to expand our long-term
business opportunities; the conduct and results of our various clinical
trials; financial projections and estimates and their underlying assumptions;
and future performance. All of such statements are subject to certain risks
and uncertainties, many of which are difficult to predict and generally beyond
the control of the Company, that could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements.

These factors include, among others, the Company's failure to successfully and
timely develop new products; the Company's collaborative relationships and the
financial risks related thereto; the Company's ability to comply with its
obligations under license agreements; the risks inherent in the early stages
of drug development and in conducting clinical trials; the Company's inability
to obtain regulatory approval in a timely manner or at all; the Company's
history of operating losses and the potential for future losses, which may
lead the Company to not be able to continue as a going concern; the Company's
need for substantial additional financing to meet its business objectives; the
potential for the loss of funding from the Company's R&D grants and contracts
and its ability to win additional funding under such grants and contracts.
Some of these factors could cause future results to materially differ from the
recent results or those projected in forward-looking statements.See also the
"Risk Factors" and "Forward-Looking Statements" described in the Company's
periodic filings with the Securities and Exchange Commission.

Contacts:
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com

Annie Deck-Miller, Senior Media Relations Manager
Roswell Park Cancer Institute
T: (716) 845-8593
E: annie.deck-miller@roswellpark.org

Cleveland BioLabs, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.